Tirzepatide (Mounjaro/Zepbound) Sales Projections

2024202520262027202820292030015304560Sales (Billion $)
  • Conservative Projection
  • Optimistic Projection
Data sources: Eli Lilly financial reports, analyst estimates, GlobalData, EvaluatePharma

Key Analyst Projections:

  • UBS: Estimates peak sales of $25 billion for Mounjaro
  • Bank of America: Projects annual sales could hit $48 billion
  • GlobalData: Forecasts $27 billion by 2029 for Mounjaro, $27.2 billion by 2030 for Zepbound
  • Goldman Sachs: Projects global anti-obesity market at $100 billion by 2030
  • EvaluatePharma: Projects $17 billion in sales by 2028